- Cabaletta Bio, Inc. is a clinical-stage biotechnology company aiming to develop engineered T-cell therapies for B-cell-mediated autoimmune diseases.
- Cabaletta has 3 potential therapeutics from its therapeutic platform of autologous autoantibody receptor T Cells for autoimmune diseases with its lead Phase 1 therapeutic, DSG3-CAART, aiming to treat mucosal pemphigus Vulgaris ("MPV").
- Cabaletta since its inception in 2017 has been financed from the sale of convertible notes/preferred stock (+$86M) and its 2019 IPO (+$71M) funding operations till 3Q 2022 (Cash 9m2020: $118M).
- Cabaletta's next catalyst expected in 1H 2021 is DSG3-CAART's expected acute safety data-release from its cohort-1 patients dosed in December 2020 and additional topline data on completed dose cohorts in 2H 2021.
- In summary, the author projects Cabaletta Bio, Inc. as a very risky "buy" at a 7-year price target of $50 (+259% upside).
For further details see:
Cabaletta: DSG3-CAART's 1H 2021 Data Release Can Substantiate This Young Biotech